Advertisement

Effect of a diffusional barrier to a metabolite across hepatocytes on its kinetics in “enzyme-distributed” models: A computer-aided simulation study

  • Seiji Miyauchi
  • Yuichi Sugiyama
  • Hitoshi Sato
  • Yasufumi Sawada
  • Tatsuji Iga
  • Manabu Hanano
Article

Abstract

The effect of a diffusional barrier to a metabolite between the blood and hepatocytes on elimination kinetics of formed and preformed metabolites was predicted under various enzymic distributions in the liver by computer- aided simulation. Sequential metabolism by which the primary metabolite (MI) is generated from the parent drug (D) and further metabolized to the terminal metabolite (MII) by enzymes A and B, respectively, was chosen for the simulation. Moreover, four models of enzymic distribution patterns were defined with regard to the hepatic blood flow path. The extraction ratios for the preformed and formed metabolites (designated as Em and Ep→m, respectively) were simulated by varying both the average intrinsic clearance of enzyme B (\(\overline {CL_{int,B} }\)) and the permeability of hepatocytes for MI (\(\overline {P_m }\)), while keeping the average intrinsic clearance of enzyme A (\(\overline {CL_{int,A} }\)) equal to hepatic blood flow (Q). When a rapid equilibrium of MI between the blood and hepatocytes held, i.e.,\(\overline {P_m }\) was large relative to Q, Em was equal to or higher than Ep→m for all models, as previously shown by Pang and Stillwell. By contrast, it was found that when a diffusional barrier for MI existed, i.e.,\(\overline {P_m }\) was small relative to Q, Em was equal to or lower than Ep→m. Furthermore, it was observed that the smaller\(\overline {P_m }\) became, the larger the difference between Em and Ep→m became. We further simulated the effect of the intrinsic clearance (\(\overline {CL_{int,C} }\)) for a metabolic pathway, which competes for that by enzyme A. on the Epm value. In the model assuming even distribution of all the enzymes along the flow path, irrespective of the\(\overline {CL_{int,C} }\) value, a similar effect of\(\overline {P_m }\) on Ep→m was observed when the\(\overline {P_m }\) value was relatively small (\(\overline {P_m }< Q\)). By contrast, in the case of uneven enzymic distributions of enzymes A and B, the effect of the\(\overline {CL_{int,C} }\) value on the relationship between Pm and Ep→m occurred to some extent. From these simulations, it was concluded that lower membrane permeability (\(\overline {P_m }\)) both diminishes the entry of preformed metabolite into the hepatocytes and accelerates the removal of intracellularly formed metabolite (through sequential metabolism) by diminishing its efflux, yielding lower Em than Ep→m. When\(\overline {P_m }\) becomes small (\(\overline {P_m }< 1/10Q\)), these mechanisms for lower Em than Ep→m predominate over other mechanisms such as the presence of a competing metabolic route and uneven distribution of enzymes.

Key words

diffusional barrier hepatic extraction enzyme-distributed model metabolite kinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. J. Atkinson and J. M. Strong. Effect of active drug metabolites on plasma levels response correlations.J. Pharmacokin, Biopharm. 5:95–109 (1977).CrossRefGoogle Scholar
  2. 2.
    J. Blumer, J. M. Strong, and A. J. Atkinson. The convulsant potency of lidocaine and its N-dealkylated metabolites.J. Pharmaco. Exp. Ther. 186:31–36 (1973).Google Scholar
  3. 3.
    J. R. De Baun, J. Y. R. Smith, E. C. Miller, and J. A. Miller. Reactivityin vivo of the carcinogenN-hydroxy-2-acetylaminofluorene:Increase by sulfate ion.Science 167:184–186 (1970).CrossRefGoogle Scholar
  4. 4.
    D. E. Drayer. Pharmacologically active drug metabolites:Therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.Clin Pharmacokin. 1:426–443 (1976).CrossRefGoogle Scholar
  5. 5.
    K. S. Pang and R. Gillette. Kinetics of metabolite formation and elimination in the perfused rat liver preparation:Differences between the elimination of preformed acetaminophen and acetaminophen formed from phenacetin.J. Pharmacol. Exp. Ther. 207:178–194 (1978).PubMedGoogle Scholar
  6. 6.
    K. S. Pang and J. A. Terrell. Retrograde perfusion to probe the heterogeneous distribution of hepatic drug metabolizing enzymes in rats.J. Pharmacol Exp. Ther. 216:339–346 (1981).PubMedGoogle Scholar
  7. 7.
    K. S. Pang, L. Waller, M. G. Horning, and K. K. Chan. Metabolite kinetics:Formation of acetaminophen from deuterated and nondeuterated phenacetin and acetanilide on acetaminophen sulfation kinetics in the perfused rat liver.J. Pharmaco. Exp. Ther. 222:14–19 (1982).Google Scholar
  8. 8.
    J. Baron, J. A. Redick, and F. P. Guengerich. Immunohistochemical localizations of cytochromes P-450 in rat liver.Life Sci 23:2627–2632 (1978).PubMedCrossRefGoogle Scholar
  9. 9.
    J. G. Conway, F. C. Kauffman, S. Ji, and R. G. Thurman. Ratio of sulfation and glucuronidation of 7-hydroxycoumarin in periportal and pericentral regions of the liver lobule.Mol. Pharmacol. 22:509–516 (1982).PubMedGoogle Scholar
  10. 10.
    K. Tonda, T. Hasegawa, and M. Hirata. Effects of phenobarbital and 3-methylcholanthrene pretreatments on monooxygenase activities and proportions of isolated rat hepatocyte subpopulation.Mol. Pharmacol. 23:235–243 (1983).PubMedGoogle Scholar
  11. 11.
    N. H. Stacey and C. D. Klaassen. Uptake of galactose, ouabain and taurocholate into centrilobular and periportal enriched hepatocyte subpopulations.J. Pharmacol. Exp. Ther. 216:634–639 (1981).PubMedGoogle Scholar
  12. 12.
    K. S. Pang, H. Koster, I. C. M. Halsema, E. Scholtens, G. J. Mulder, and R. N. Stillwell. Normal and retrograde perfusion to probe the zonal distribution of sulfation and glucuronidation activites of harmol in the perfused rat liver preparation.J. Pharmacol. Exp. Ther. 224:647–653 (1983).PubMedGoogle Scholar
  13. 13.
    K. S. Pang and R. N. Stillwell. An understanding of the role of enzyme localization of the liver on metabolite kinetics: A computer simulation.J. Pharmacokin. Biopharm. 11:451–468 (1983).CrossRefGoogle Scholar
  14. 14.
    K. S. Pang and M. Rowland. Hepatic clearance of drugs. I. Theoretical considerations of a “Well-stirred” model and a “Parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.J. Pharmacokin. Biopharm. 11:625–653 (1977).CrossRefGoogle Scholar
  15. 15.
    K S. Pang, P. Kong, J. A. Terrell, and R. E. Billings. Metabolism of acetaminophen and phenacetin by isolated rat hepatocytes.Drug. Metab. Dispos. 13:42–50 (1984).Google Scholar
  16. 16.
    K. S. Pang, W. F. Cherry, J. A. Terrell, and E. H. Ulm. Disposition of enalapril and its diacid metabolite, enalaprilat in a perfused rat liver preparation.Drug. Metab. Dispos. 12:309–313 (1984).PubMedGoogle Scholar
  17. 17.
    K. S. Pang, W. F. Cherry, and E. H. Ulm. Disposition of enalapril in the perfused rat intestine-liver preparation:Absorption, metabolism and first-pass effect.J. Pharmacol. Exp. Ther. 233:788–795 (1985).PubMedGoogle Scholar
  18. 18.
    A. M. Lannoy and K. S. Pang. Presence of a diffusional barrier on metabolite kinetics.Drug. Metab. Dispos. 14:513–520 (1986).PubMedGoogle Scholar
  19. 19.
    H. Sato, Y. Sugiyama, M. Miyauchi, T. Iga, and M. Hanano. A simulation study on the effect of a uniform diffusional barrier across hepatocytes on drug metabolism by evenly or unevenly distributed unienzyme in the liver.J. Pharm. Sci. 75:3–8 (1986).PubMedCrossRefGoogle Scholar
  20. 20.
    P. O. Seglen. Preparation of rat liver cells. III. Enzymatic requirement for tissue dispersion.Exp. Cell Res. 82:391–398 (1973).PubMedCrossRefGoogle Scholar
  21. 21.
    A. M. Lannoy and K. S. Pang. Effect of diffusional barrier on drug and metabolite kinetics II.Drug Metab. Dispos. 15:51–58 (1987).PubMedGoogle Scholar
  22. 22.
    D. W. Sundheimer and K. Brendel. Metabolism of harmol and transport of harmol conjugates in isolated rat hepatocytes.Drug Metab. Dispos. 5:433–440 (1983).Google Scholar
  23. 23.
    S. Miyauchi, Y. Sugiyama, T. Iga and M. Hanano. Membrane-limited transport of conjugative metabolites of 4-methylumbelliferone in rats. Proceeding of the Eighth Symposium on Drug Interaction with Biological Membrane, Okayama 1985, pp. 50–51.Google Scholar
  24. 24.
    W. J. Brock and M. Vore. Characterization of uptake of steroid glucuronides into isolated male and female rat hepatocytes.J. Pharmacol. Exp. Ther. 229:175–181 (1984).PubMedGoogle Scholar
  25. 25.
    L. R. Schwarz, R. Gotz, and C. D. Klaassen. Uptake of sulfobromophthalein-glutathione conjugate by isolated hepatocytes.Am. J. Physiol. 239:C118-C123 (1980).PubMedGoogle Scholar
  26. 26.
    K. J. Baker and S. E. Bradley. Binding of sulfobromophthalein (BSP) sodium by plasma albumin. Its role in hepatic BSP extraction.J. Clin. Invest. 45:281–287 (1966).PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    T. Iga, D. L. Eaton, and C. D. Klaassen. Uptake of unconjugated bilirubin by isolated rat hepatocytes.Am. J. Physiol. 236:C9-C14 (1979).PubMedGoogle Scholar
  28. 28.
    E. L. Forker and B. A. Luxon. Albumin helps mediate removal of taurocholate by rat liver.J. Clin. Invest. 67:1517–1522 (1981).PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1987

Authors and Affiliations

  • Seiji Miyauchi
    • 1
  • Yuichi Sugiyama
    • 1
  • Hitoshi Sato
    • 1
  • Yasufumi Sawada
    • 1
  • Tatsuji Iga
    • 1
  • Manabu Hanano
    • 1
  1. 1.Faculty of Pharmaceutical SciencesUniversity of TokyoTokyoJapan

Personalised recommendations